Medicare payment cuts went into effect Monday for many hospitals participating in the 340B Drug Pricing Program after a federal district judge dismissed a last-minute effort to stop them. Read More
Selecta Biosciences Inc., of Watertown, Mass., said the FDA accepted the IND for a combination therapeutic candidate consisting of SVP-Rapamycin and LMB-100 (Selecta's SEL-403 product candidate) for the treatment of mesothelioma patients. Read More
Spectrum Pharmaceuticals Inc., of Henderson, Nev., named Joseph W. Turgeon, president and CEO; Thomas J. Riga chief operating officer; and Stuart M. Krassner board chairman. Read More
Seattle Genetics Inc., of Bothell, Wash., said the FDA accepted for filing a supplemental BLA for Adcetris (brentuximab vedotin) in combination with chemotherapy for the front-line treatment of patients with advanced classical Hodgkin's lymphoma (HL). Read More
Dnanexus Inc., of Mountain View, Calif., said it closed a $58 million financing led by new investor Foresite Capital with strategic investment from Microsoft with existing investors GV (formerly Google Ventures), TPG Biotech, Wuxi Nextcode, Claremont Creek Ventures and Midcap Financial also participating. The company's global platform enables a network of enterprises to gain insight from large genomic and biomedical datasets. Read More
PERTH, Australia – Unlike its Australian peers, regenerative medicine company Regeneus Ltd. is not focusing on the U.S. market. Instead, it's placing its bets on Japan first and then will move out to other territories. Read More
HONG KONG – As it works to upgrade its biologics industry and the vaccine sector in particular, China updated the approval process for new products. Read More
If Amgen Inc. and Novartis AG win approval of the calcitonin gene-related peptide (CGRP) inhibitor Aimovig (erenumab) – the PDUFA date is May 17 – the compound's price tag could provide guidance for others with CGRP monoclonal antibodies in their migraine pipelines, such as Alder Biopharmaceutical Inc., with eptinezumab due to yield phase III data this quarter from the PROMISE 2 (Prevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 2) trial in chronic migraine. Read More
Neximmune Inc. played its cards close to the vest after disclosing its acquisition a year ago by the Barer & Son Capital-led syndicate that included Sol Barer, chairman of Teva Pharmaceutical Industries Ltd. and former chairman and CEO of Celgene Corp., Joshua Barer, managing director of Sunflower Life Sciences, and William Hawkins, former chairman and CEO of Medtronic plc. Read More
Just days before one of biotech's busiest weeks, a quartet of IPO filings by Menlo Therapeutics Inc., Restorbio Inc., Armo Biosciences Inc. and Solid Biosciences LLC are outlining the case for investing millions of dollars in the development of new therapies. Read More
LONDON – As the row over drug pricing gets louder, the return on investment (ROI) among the top 12 pharma companies continues to slide, according to the latest annual survey carried out by consultants at Deloitte LLP. Read More
